Correlation Between the Thyroid Hormone Levels and Type 2 Diabetes Mellitus in Non-Alcoholic Fatty Liver Disease.

PubMed1 Jan 2026Diabetes, metabolic syndrome and obesity : targets and therapy● 3/10i

Correlation Between the Thyroid Hormone Levels and Type 2 Diabetes Mellitus in Non-Alcoholic Fatty Liver Disease.

Bian L, Fan H, Yu Q, Rao X, Tang T et al.

The FT3/FT4 ratio shows moderate discriminatory performance for type 2 diabetes in patients with NAFLD, with those in the highest quartile having 73% lower odds of diabetes (OR 0.27). Retrospective analysis of 4,942 hospitalized patients with NAFLD at one Chinese center, 2020-2023. This provides the first evidence that thyroid hormone ratios could serve as metabolic risk markers in NAFLD populations, potentially offering a novel biomarker approach. Single-center Chinese data may limit generalizability to other populations.

Strategic Signal

This biomarker research creates no immediate commercial impact but adds to the growing evidence base linking thyroid function to metabolic disease. The moderate discriminatory performance (AUC 0.668) falls short of clinical utility thresholds typically required by regulatory bodies like FDA for diagnostic claims. The finding may influence future metabolic drug development strategies by highlighting thyroid-liver-diabetes interconnections, particularly for companies developing NAFLD therapies who could incorporate thyroid monitoring into their clinical programs.

Type 2 diabetesLiver/NASH

Original Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are significant metabolic disorders that frequently coexist and share interrelated pathophysiological mechanisms. Thyroid hormones (THs) play multifaceted roles in metabolic regulation. This study explored the association between THs-particularly the free triiodothyronine (FT3) to free thyroxine (FT4) ratio (FT3/FT4)-and T2DM among NAFLD individuals. PATIENTS AND METHODS: A total of 4942 patients with NAFLD hospitalized at the Affiliated Hospital of Hangzhou Normal University between 2020 and 2023 were retrospectively analyzed. Partial correlation analysis controlling for age and sex was conducted to investigate the relationships between THs and the FT3/FT4 ratio with hemoglobin A1c (HbA1c) and fasting blood glucose (FBG) in NAFLD patients with T2DM. Meanwhile, the association between the FT3/FT4 ratio and T2DM was assessed by binary logistic regression. Receiver operating characteristic (ROC) curve analysis was performed to assess the discriminatory ability of the FT3/FT4 ratio for T2DM. RESULTS: Patients with T2DM had significantly lower FT3, TT3, and the FT3/FT4 ratio, while higher FT4, compared with those without. Partial correlation analysis further showed the negative correlation of FT3, TT3, and the FT3/FT4 with HbA1c and FBG, with the FT3/FT4 ratio showing the strongest correlation with HbA1c (r = -0.222, p < 0.001). After adjusting for confounding factors, individuals in the highest FT3/FT4 quartile had a markedly reduced likelihood of T2DM relative to those in the lowest quartile (OR 0.27, 95% CI 0.23-0.33; p < 0.001). ROC analysis showed a moderate discriminatory performance of the FT3/FT4 ratio for T2DM (AUC up to 0.668). CONCLUSION: In patients with NAFLD, a lower FT3/FT4 ratio was significantly associated with T2DM and poorer glycemic status. Compared with individual TH levels, the FT3/FT4 ratio may serve as a more integrative marker of metabolic risk in this population.

View original source ↗

Related signals

Strategic Signal

FDA1 Apr 2026New Drug Approval (NDA/BLA)High impact● 10/10i

FDA Approves Foundayo (Orforglipron) — New Drug Approval (NDA/BLA)

FDA approved orforglipron (Foundayo, Eli Lilly) for type 2 diabetes -- a once-daily oral small-molecule GLP-1 receptor agonist. Orforglipron is the first non-peptide oral GLP-1 approved in the US; oral semaglutide (Rybelsus, Novo Nordisk) has been approved for T2D since 2019 and expanded to obesity in January 2026. Unlike Rybelsus, orforglipron requires no fasting or water volume restrictions before dosing.

GLP-1Type 2 diabetesPricing/accessEli Lilly Novo Nordisk

Strategic Signal

Clinical Trial17 Apr 2026Phase 3High impact● 8/10i

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3 open-label trial compared once-daily oral orforglipron versus insulin glargine in people with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study enrolled 2,749 participants with primary endpoint of time to first major adverse cardiovascular event, completed in March 2026. Eli Lilly is positioning orforglipron as a cardiovascular outcomes option in high-risk populations, directly competing with established insulin therapy in this indication. This represents the first cardiovascular outcomes trial for orforglipron following its April 2026 FDA approval for type 2 diabetes.

GLP-1Type 2 diabetesWeight lossCardiovascularEli Lilly

Strategic Signal

Clinical Trial13 Apr 2026Phase 3High impact● 8/10i

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial

Phase 3 trial evaluating retatrutide once weekly in adults with type 2 diabetes who have obesity or overweight, including a subset with obstructive sleep apnea. Enrolling 1,000 participants across 89 weeks with completion expected May 2026, measuring weight reduction and sleep apnea improvement versus placebo. Eli Lilly advances retatrutide into dual indication territory, competing directly with Novo Nordisk's semaglutide and their own tirzepatide in the expanding cardiometabolic space. The inclusion of sleep apnea patients follows Zepbound's December 2024 OSA approval, positioning retatrutide for multiple obesity comorbidities.

GLP-1Weight lossType 2 diabetesEli Lilly Novo Nordisk

Strategic Signal

FDA1 Apr 2026FDA Press ReleaseHigh impact● 8/10i

FDA Approves First New Molecular Entity Under National Priority Voucher Program

FDA approved Foundayo (orforglipron) on April 1, 2026, marking the fifth approval under the Commissioner's National Priority Voucher pilot program. This represents approval of the first small-molecule oral GLP-1 receptor agonist, distinct from the peptide-based oral semaglutide (Rybelsus) approved by FDA in 2019. Eli Lilly gains competitive positioning in the oral GLP-1 space with a differentiated mechanism that requires no fasting restrictions. The approval leverages FDA's expedited voucher pathway designed to incentivize development of treatments addressing unmet medical needs.

GLP-1Type 2 diabetesEli Lilly